Filing identity and reporting period
The supplied filing is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019, filed May 9, 2019. This does not match the request metadata naming “Solana Co”; verify the issuer before relying on this summary. Amounts below are U.S. dollars unless noted; financial statement amounts are in millions, except per-share data.
Business context
Helius is a neurotechnology company developing the PoNS device and treatment. PoNS was authorized in Canada for a specified balance-deficit indication; the company reported first Canadian commercial sales to two clinics during the quarter. The device did not have U.S., European or Australian marketing authorization at the time described in the filing.
Key financial metrics
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | $0.677 | $0 |
| Cost of sales / gross profit | $0.236 / $0.441 | $0 / $0 |
| Gross margin | About 65% | Not applicable |
| R&D expense | $2.681 | $2.552 |
| SG&A expense | $4.581 | $2.165 |
| Operating loss | $(6.821) | $(4.717) |
| Net income (loss) | $1.324 | $(1.165) |
| Operating cash flow | $(6.800) | $(4.860) |
| Cash and total assets, March 31 | $18.656 / $22.498 | Cash at Dec. 31, 2018: $25.583 |
| Total liabilities / stockholders’ equity, March 31 | $10.480 / $12.018 | Liabilities at Dec. 31, 2018: $17.973 |
Net income included an $8.289 million noncash gain from the change in fair value of derivative financial instruments. The company remained loss-making from operations. Cash decreased $6.927 million in the quarter. Working capital, defined by the company excluding derivative liabilities, was $16.691 million, down from $22.757 million at year-end. No conventional borrowings are identified in the presented balance sheet; liabilities included $5.743 million of warrant-related derivative instruments and $0.745 million of operating lease obligations.
Material changes versus prior period
- PoNS product sales generated $0.677 million of first-quarter revenue, versus none in Q1 2018.
- Operating expenses rose $2.545 million, principally from higher headcount and commercial operations costs; SG&A increased $2.416 million.
- Cash used in operations increased by $1.940 million year over year.
- Net income improved largely because the noncash derivative fair-value gain increased to $8.289 million from $2.525 million, not because operating performance turned profitable.
- Derivative liabilities fell to $5.743 million from $13.769 million at December 31, 2018.
Outlook, risks and unusual items
- Management said existing capital resources were expected to fund operations through the end of Q4 2019, while warning that additional funding would be needed and might not be available on acceptable terms. The filing states that substantial doubt exists about the company’s ability to continue as a going concern.
- In April 2019, the FDA declined the company’s request for de novo classification and marketing authorization. The FDA cited insufficient information to distinguish the device’s contribution from physical therapy. Management planned to seek further FDA feedback, generate additional data and pursue resubmission; U.S. commercialization timing and pathway were uncertain.
- Following the FDA decision, the company said it reduced its workforce by more than 30%, prioritized Canadian commercialization and U.S. resubmission, and put its clinical experience program on hold.
- On May 6, 2019, the company submitted an application for Australian marketing authorization. It also had a CE-mark application pending in Europe.
- Altair LLC gave notice terminating its distribution agreement, effective May 20, 2019; the company said it was discussing a replacement agreement.
- The company’s 50/50 strategic arrangement with Heuro included a remaining funding obligation of up to CAD$0.6 million, identified as its maximum exposure to loss. A $2.0 million contractual penalty tied to U.S. Army availability requirements was assessed as remote after the requirement was amended and met.
- Warrant fair-value movements are noncash and depend on valuation assumptions, including stock price and volatility. Foreign-exchange exposure was unhedged.
Important facts for investors to verify
- Confirm the issuer: the filing is for Helius Medical Technologies, Inc. (Nasdaq: HSDT), not Solana Co.
- Check subsequent FDA communications, the evidence required for resubmission, and potential need for a more burdensome PMA pathway.
- Assess actual cash burn, financing availability and runway against management’s Q4 2019 estimate.
- Verify whether Canadian clinic sales expanded and whether reimbursement discussions produced coverage or payment arrangements.
- Review warrant terms and fair-value assumptions, which materially affected reported net income and liabilities.
- Check the outcome of the Altair negotiations and the scale of Heuro’s ongoing funding commitments.